204 related articles for article (PubMed ID: 10772967)
1. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
Cheung KL; Graves CR; Robertson JF
Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
[TBL] [Abstract][Full Text] [Related]
2. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
Cheung KL; Robertson FR
Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
[TBL] [Abstract][Full Text] [Related]
3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
4. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
[TBL] [Abstract][Full Text] [Related]
9. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients.
Jäger W; Eibner K; Löffler B; Gleixner S; Krämer S
Anticancer Res; 2000; 20(6D):5179-82. PubMed ID: 11326691
[TBL] [Abstract][Full Text] [Related]
10. [Biomarkers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
[TBL] [Abstract][Full Text] [Related]
11. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
12. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
13. Midkine in plasma as a novel breast cancer marker.
Ibusuki M; Fujimori H; Yamamoto Y; Ota K; Ueda M; Shinriki S; Taketomi M; Sakuma S; Shinohara M; Iwase H; Ando Y
Cancer Sci; 2009 Sep; 100(9):1735-9. PubMed ID: 19538527
[TBL] [Abstract][Full Text] [Related]
14. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
15. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
Nicolini A; Carpi A; Ferrari P; Rossi G
Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
[TBL] [Abstract][Full Text] [Related]
18. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
19. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
20. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]